KDMN

Q3'20

Last Updated:

Kadmon Corporation

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Cash

$159.7M

Burn Rate (Quarterly)

-$24.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

CLOVIQUE™ (Trientine Hydrochloride Capsules, USP)

Wilson's disease

Quarterly Sales (Approved)

March 05, 2021 (Est)

Belumosudil (KD025) (Selective ROCK2 inhibitor)

Chronic Graft versus Host Disease (cGVHD)

NDA Acceptance

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon